|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's range||162.05 - 164.74|
|52-week range||132.24 - 243.52|
|Beta (5Y monthly)||0.55|
|PE ratio (TTM)||26.58|
|Earnings date||24 Jan 2024 - 29 Jan 2024|
|Forward dividend & yield||1.92 (1.17%)|
|Ex-dividend date||08 Nov 2023|
|1y target est||178.38|
Published in the Journal of the American Medical Association Network Open, study estimates global COPD burden from 2020 through 2050 Study projects disproportionate growth in COPD among women and low-middle income regions SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the results of a study on the global burden of Chronic Obstructive Pulmonary Disease (COPD) through 2050. Published in the Journal of the American Medical Association (JAMA) Network Open,
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.